Ignite Creation Date:
2024-05-05 @ 11:51 AM
Last Modification Date:
2024-10-26 @ 9:15 AM
Study NCT ID:
NCT00159679
Status:
COMPLETED
Last Update Posted:
2021-01-25
First Post:
2005-09-08
Brief Title:
Pregabalin in the Treatment of Pain Due to Diabetic Peripheral Neuropathy
Sponsor:
Pfizers Upjohn has merged with Mylan to form Viatris Inc
Organization:
Pfizer
Study Overview
Official Title:
A 13 Week Double-Blind Placebo-Controlled Phase 4 Trial of Pregabalin CI-1008 600 mgDay for Relief of Pain in Subjects With Painful Diabetic Peripheral Neuropathy
Status:
COMPLETED
Status Verified Date:
2009-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purposes of this study are to 1 find out if pregabalin relieves pain in subjects with painful diabetic peripheral neuropathy 2 find out if pregabalin is safe at a dose of 600 mgday taken twice a day and 3 find out if changes in nerve function happen during the study
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None